Analyst Jonna Kim of TD Cowen maintained a Hold rating on Hims & Hers Health, retaining the price target of $48.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jonna Kim has given his Hold rating due to a combination of factors influencing Hims & Hers Health’s current market position. The company’s growth trajectory appears to be slowing, with data indicating a deceleration in key business areas and tougher year-over-year comparisons ahead. Despite solid demand for compounded GLP-1 products, the core hims.com business is experiencing moderation, which impacts the overall growth outlook.
Additionally, while the upcoming 3Q25 earnings are expected to align with market expectations, there is a lack of significant upside potential in the near term. This is partly due to muted demand for the core brand and elevated short interest in the stock. Although there is encouraging demand for GLP-1 products, the growth rate is moderating, and newer initiatives are not expected to contribute meaningfully until 2026. These factors collectively contribute to the Hold rating, as the near-term setup for the stock remains challenging.
According to TipRanks, Kim is a 3-star analyst with an average return of 13.1% and a 34.21% success rate. Kim covers the Consumer Cyclical sector, focusing on stocks such as American Eagle, Bath & Body Works, and Olaplex Holdings.